Evidence map›Paper›PMID 36732482›Full record

ArticleEuropean journal of pediatrics2023

Mortality predictive factors in congenital hepatic hemangioma: a case-control study.

Carlos Delgado-Miguel, Paloma Triana, Miriam Miguel-Ferrero, Mercedes Díaz, Loreto Hierro, Paloma Jara, Juan Carlos López-Gutiérrez, Francisco Hernández Oliveros

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of pediatrics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Observational
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Carlos Delgado-MiguelDepartment of Pediatric Surgery, La Paz Children's University Hospital, Paseo de La Castellana 261, Madrid, Spain. carlosdelgado84@hotmail.com.
Paloma TrianaDepartment of Pediatric Surgery, La Paz Children's University Hospital, Paseo de La Castellana 261, Madrid, Spain.
Miriam Miguel-FerreroDepartment of Pediatric Surgery, La Paz Children's University Hospital, Paseo de La Castellana 261, Madrid, Spain.
Mercedes DíazDepartment of Pediatric Surgery, La Paz Children's University Hospital, Paseo de La Castellana 261, Madrid, Spain.
Loreto HierroDepartment of Pediatric Hepatology, La Paz Children's University Hospital, Madrid, Spain.
Paloma JaraDepartment of Pediatric Hepatology, La Paz Children's University Hospital, Madrid, Spain.
Juan Carlos López-GutiérrezDepartment of Pediatric Surgery, La Paz Children's University Hospital, Paseo de La Castellana 261, Madrid, Spain.
Francisco Hernández OliverosDepartment of Pediatric Surgery, La Paz Children's University Hospital, Paseo de La Castellana 261, Madrid, Spain.
Hospital Universitario La Paz · ESHospital La Paz Institute for Health Research · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Congenital hepatic hemangiomas (CHHs) are benign vascular tumors whose clinical, histological, and genetic correlation has recently been described in patients with long-term survival, although no mortality risk factors have been identified to date. The aim of this study is to analyze predictors of mortality in patients with CHH. A retrospective single-center case-control study of consecutive CHH patients diagnosed in our institution between 1991 and 2021 was performed, who were classified into two groups according to their survival. Demographic, gestational, imaging, and laboratory data at diagnosis were collected and compared between both groups. A total of 29 patients were included (12 males; 17 females) of whom 5 died as a result of CHH evolution due to cardiac failure and coagulopathy, with a median age of 11 days until death. No differences in demographic or gestational data were reported. There were neither differences when comparing imaging tests, nor in location, number of affected liver segments, or CHH estimated volume. Upon laboratory data at diagnosis, deceased patients had a significant elevation of median liver enzymes [glutamic-oxaloacetic transaminase (359 u/L vs. 45 u/L; p < 0.01) and glutamic-pyruvic transaminase (313 u/L vs. 20 u/L; p < 0. 01)], as well as a decreased median platelet count (85,250/µL vs. 337,000/µL; p < 0.01), prothrombin activity (54% vs. 93%; p < 0.01), and fibrinogen (131 mg/dL vs. 284 mg/dL; p < 0.01), with no differences in blood count or biochemistry data.

conclusionsCHH clinical behavior can be innocuous or life-threatening. Thrombocytopenia, coagulation disorders, and increased liver enzymes at diagnosis seem to be the main predictors of mortality. WHAT IS KNOWN: • Congenital Hepatic Hemangiomas (CHHs) are benign vascular tumors whose clinical behavior can be innocuous or life-threatening. WHAT IS NEW: • Thrombocytopenia, coagulation disorders and increased liver enzymes at diagnosis seem to be the main predictors of mortality in these patients.

Indexed as

Blood Coagulation DisordersHemangiomaLiver NeoplasmsThrombocytopeniaVascular NeoplasmsCase-Control StudiesFemaleHumansInfant, NewbornMaleRetrospective StudiesCoagulation disordersCongenital hepatic hemangiomaLiver enzymesThrombocytopeniaVascular tumor

Identifiers

PMID36732482
OpenAlexW4319063636

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.